Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 12% Improvement Relative Risk Mortality (b) 57% HCQ  Hernandez-Cardenas et al.  LATE TREATMENT  RCT Is late treatment with HCQ beneficial for COVID-19? RCT 214 patients in Mexico (April - July 2020) No significant difference in mortality c19hcq.org Hernandez-Cardenas et al., medRxiv, Feb 2021 Favors HCQ Favors control

Hydroxychloroquine for the treatment of severe respiratory infection by COVID-19: a randomized controlled trial

Hernandez-Cardenas et al., medRxiv, doi:10.1101/2021.02.01.21250371
Feb 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Very late stage RCT with 214 patients, mean SpO2 65%, 162 on mechanical ventilation, showing no significant difference in mortality.
Patients not intubated at baseline show greater improvement, HR 0.43 [0.09-2.03].
Table 4 shows different results to the abstract - table 4 adjusted HR 0.80 [0.51-1.23], abstract HR 0.88 [0.51-1.53]. There was no significant difference in severe adverse events.
risk of death, 12.0% lower, RR 0.88, p = 0.66, treatment 106, control 108.
risk of death, 57.0% lower, RR 0.43, p = 0.29, subgroup not intubated at baseline.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hernandez-Cardenas et al., 5 Feb 2021, Randomized Controlled Trial, Mexico, preprint, 6 authors, study period 8 April, 2020 - 12 July, 2020, average treatment delay 7.4 days.
This PaperHCQAll
HYDROXYCHLOROQUINE FOR THE TREATMENT OF SEVERE RESPIRATORY INFECTION BY COVID-19: A RANDOMIZED CONTROLLED TRIAL
Carmen Hernandez-Cardenas, Ireri Thirion-Romero, Norma E Rivera-Martinez, Patricia Meza-Meneses, Arantxa Remigio-Luna, Rogelio Perez-Padilla
doi:10.1101/2021.02.01.21250371
The novel coronavirus pandemic (COVID-19) represents a major public health problem due to its rapid spread and its ability to generate severe pneumonia. Thus, it is essential to find a treatment that reduces mortality. Our objective was to estimate whether treatment with 400 mg/day of Hydroxychloroquine for 10 days reduces in-hospital mortality in subjects with severe respiratory disease due to COVID-19 compared with placebo. Material and methods: A double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of Hydroxychloroquine for the treatment of severe disease by COVID-19 through an intention-to-treat analysis. Eligible for the study were adults aged more than 18 years with COVID-19 confirmed by RT-PCR and lung injury requiring hospitalization with or without mechanical ventilation. Primary outcome was 30-day mortality. Secondary outcomes: days of mechanical ventilation, days of hospitalization and cumulative incidence of serious adverse events. Results: A total of 214 patients with COVID-19 were recruited, randomized and analyzed. They were hypoxemic with a mean SpO2 of 65% ± 20, tachycardic (pulse rate 108±17 min-1 ) and tachypneic (32 ±10 min-1 ); 162 were under mechanical ventilation at randomization. Thirty-day mortality was similar in both groups (38% in Hydroxychloroquine vs. 41% in placebo, hazard ratio [HR] 0.88, 95% Confidence Interval [95%CI] 0.51-1.53). In the surviving participants, no significant difference was found in secondary outcomes. Conclusion: No beneficial effect or significant harm could be demonstrated in our randomized controlled trial including 214 patients, using relatively low doses of Hydroxychloroquine compared with placebo in hospitalized patients with severe COVID-19. .
Analysis Follow-Up Randomized (n= 214) Allocation .
References
Beigel, Tomashek, Dodd, Remdesivir for the Treatment of Covid-19 -Preliminary Report, The New England journal of medicine, doi:10.1056/NEJMoa2007764
Chan, Yuan, Kok, A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster, Lancet
Chen, Zhou, Dong, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet
Holshue, Debolt, Lindquist, First Case of 2019 Novel Coronavirus in the United States, The New England journal of medicine
Horby, Lim, Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report, The New England journal of medicine
Marshall, Murthy, Diaz, A minimal common outcome measure set for COVID-19 clinical research, The Lancet Infectious Diseases
Mercuro, Yen, Shim, Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19), JAMA cardiology
Moher, Hopewell, Schulz, Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials, The BMJ
Saitz, Schwitzer, Communicating Science in the Time of a Pandemic, JAMA
Tisdale, Jaynes, Kingery, Development and validation of a risk score to predict QT interval prolongation in hospitalized patients, Circulation. Cardiovascular quality and outcomes
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell research
Zhou, Yang, Wang, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature
Zhu, Zhang, Wang, A Novel Coronavirus from Patients with Pneumonia in China, 2019, The New England journal of medicine
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit